News End of the line for Cassava's troubled Alzheimer's programme The saga of Cassava Sciences' development of Alzheimer's disease therapy simufilam has come to its dismal end.
News Augustine decloaks with $85m for nerve disease programme Belgian start-up Augustine raises €78m ($85m) in first-round funding for HDAC6 inhibitors headed by a candidate for Charcot-Marie-Tooth disease.
News Bayer gains ground in two-fronted Parkinson's offensive Bayer's cell therapy for Parkinson's disease is on the brink of a phase 3 trial, while its gene therapy has started phase 2 testing.
News Algorithm spots common sleep disorder linked to dementia An AI algorithm can help detect REM sleep behaviour disorder, which affects millions of people and is a warning signal for neurological diseases.
News Roche's Parkinson's hope fails second clinical trial Roche and Prothena's alpha-synuclein-targeting prasinezumab for Parkinson's fails again, leaving them sifting through the data for efficacy signals.
News Lilly's Alzheimer's drug Kisunla is cleared in China Eli Lilly has another approval for its anti-amyloid therapy for Alzheimer's disease, Kisunla, in China – the world's second-largest drugs market.
News Novo sues Lilly over 'misleading' GLP-1 ad campaigning The rivalry between Novo Nordisk and Eli Lilly in the GLP-1 market has spilled over into the courts in the US, with claims of misleading advertising.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
